Focusing on innovation, unveiling new vision creation.

Link to: News

News

Link to: Projects

Projects

Link to: ESG-Sustainability

ESG

News

The 2026 Chang Gung Medical Week international medical conference invited Dr. Chung-Ling Liang, MD, PhD, Chief Medical Officer of SUNHAWK VISION BIO, to deliver a lecture sharing the latest research and development of novel drugs and emerging therapeutic trends for myopia control and dry eye disease.

SUNHAWKVISION Expands Core Technology Platform to Prevent and Treat Ocular Toxicities Induced by ADC Anticancer Drugs, Filing U.S. Patent to Secure Global Strategic IP Position

The Phase II clinical trial of myopia control treatment has enrolled a total of 112 participants. Approximately 80% of the subjects have successfully completed one year of the trial. The last subject is expected to complete the study medication administration by December 31, 2026, marking the completion of the treatment phase. The trial is progressing smoothly and in line with expectations.

Sunhawk Vision Mandated by Global Mega-Pharma Titans for Exclusive One-on-One Closed-Door Summits at BIO 2026 to Leverage Strategic Licensing and Equity Bids for SHJ002 Platform.

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of May 29, 50% subjects of this trial has successfully completed the one-year treatment protocol and the remaining 50% subjects are scheduled to complete all treatment by December 2026. The study is scheduled for unblinding in the first quarter of 2027.

Sunhawk Vision Announces SHJ002 Phase 2 DED Results in NIH-Indexed Clinical Therapeutics: Breakthrough Efficacy in Corneal Repair to Redefine Global Market Landscape

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of April 2, 25 subjects have successfully completed the one-year treatment protocol. The study is scheduled for unblinding in the first quarter of 2027.

The company has successfully completed the interim review by the Data Monitoring Committee (DMC) for its Phase II clinical trial of childhood myopia treatment.

FDA approved the Phase-III clinical trial for Dry Eye Disease.

The 2026 Chang Gung Medical Week international medical conference invited Dr. Chung-Ling Liang, MD, PhD, Chief Medical Officer of SUNHAWK VISION BIO, to deliver a lecture sharing the latest research and development of novel drugs and emerging therapeutic trends for myopia control and dry eye disease.

SUNHAWKVISION Expands Core Technology Platform to Prevent and Treat Ocular Toxicities Induced by ADC Anticancer Drugs, Filing U.S. Patent to Secure Global Strategic IP Position

The Phase II clinical trial of myopia control treatment has enrolled a total of 112 participants. Approximately 80% of the subjects have successfully completed one year of the trial. The last subject is expected to complete the study medication administration by December 31, 2026, marking the completion of the treatment phase. The trial is progressing smoothly and in line with expectations.

Sunhawk Vision Mandated by Global Mega-Pharma Titans for Exclusive One-on-One Closed-Door Summits at BIO 2026 to Leverage Strategic Licensing and Equity Bids for SHJ002 Platform.

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of May 29, 50% subjects of this trial has successfully completed the one-year treatment protocol and the remaining 50% subjects are scheduled to complete all treatment by December 2026. The study is scheduled for unblinding in the first quarter of 2027.

Sunhawk Vision Announces SHJ002 Phase 2 DED Results in NIH-Indexed Clinical Therapeutics: Breakthrough Efficacy in Corneal Repair to Redefine Global Market Landscape

The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of April 2, 25 subjects have successfully completed the one-year treatment protocol. The study is scheduled for unblinding in the first quarter of 2027.

The company has successfully completed the interim review by the Data Monitoring Committee (DMC) for its Phase II clinical trial of childhood myopia treatment.

FDA approved the Phase-III clinical trial for Dry Eye Disease.

最新消息

Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.

Read more

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

Read more

Taipei Office

© Copyright – Sunhawk Vision Biotech, Inc.

design by Morcept

© Copyright – Sunhawk Vision Biotech, Inc.
design by Morcept